This webinar will explore the evolving role of chemotherapy de-escalation in early HR+/HER2− breast cancer, examining how treatment decisions can balance recurrence risk, efficacy and quality of life. It will review evidence from key studies and emerging clinical trials investigating CDK4/6 inhibitors in combination with endocrine therapy, including ribociclib, within the broader treatment landscape. The discussion will address patient selection, the role of chemotherapy, multidisciplinary decision-making and access challenges, translating current evidence into practical clinical insights.